A pending securities class action against Aardvark Therapeutics raises questions about the safety and regulatory prospects of their drug ARD-101 and its impact on investors.

Investors in Aardvark Therapeutics, Inc. have an opportunity to lead a class action lawsuit due to significant losses before the October 13, 2026 deadline.

Robbins LLP reminds Aardvark Therapeutics, Inc. investors of a class action lawsuit with a deadline of October 13, 2026 for lead plaintiff applications, due to alleged misrepresentation.

Aardvark Therapeutics, Inc. is facing a securities class action lawsuit regarding safety claims of ARD-101. Investors urged to respond by October 13, 2026.

Pomerantz LLP has initiated a class action lawsuit against Aardvark Therapeutics and its officers for misleading investors about company operations and financial prospects.

Hagens Berman announces a securities class action against Aardvark Therapeutics for alleged misrepresentation regarding the safety of ARD-101.

Aardvark Therapeutics investors with significant losses are urged to act before the October 13 deadline for potential class action involvement.

A class action lawsuit has been initiated against Aardvark Therapeutics by Pomerantz Law Firm, alleging misleading statements during the IPO process. Investors are urged to join.

A class action lawsuit has been filed against Aardvark Therapeutics, alleging misleading statements about ARD-101. Investors may be eligible for restitution.

Investors in Aardvark Therapeutics (NASDAQ: AARD) may participate in a securities fraud class action due to alleged misleading information about ARD-101.

Aardvark Therapeutics faces a class action lawsuit over misleading safety claims regarding its drug ARD-101, with major implications for investors.

Aardvark Therapeutics is embroiled in a class action lawsuit claiming misleading safety data on drug ARD-101, urging aggrieved shareholders to take action.

Aardvark Therapeutics, Inc. faces a securities class action lawsuit involving claims of misleading safety information about its drug ARD-101. Investors are urged to act.

Mit Folge 101 bricht beim RND-Fußball-Podcast „Almuths Pausen-T“ ein neues Zeitalter an. Die ARD-Sportschau ist ab sofort als Gastgeber mit im Boot. Zum Neustart sprechen Almuth Schult und Roman Gerth über das Projekt – und sie geben ihre Hot Takes für die Saison ab.

Hagens Berman has announced a securities class action lawsuit against Aardvark Therapeutics, highlighting significant safety concerns about its drug ARD-101.

A class action lawsuit has been initiated against Aardvark Therapeutics by Pomerantz LLP, involving serious allegations regarding its IPO and product safety.

Investors in Aardvark Therapeutics (NASDAQ: AARD) are alerted to a newly filed securities class action relating to false statements about its drug ARD-101.

Robbins LLP reminds investors of a class action against Aardvark Therapeutics over misleading statements regarding its IPO. Investors might be eligible for claims.

Aardvark Therapeutics (Nasdaq: AARD) reported second quarter 2026 results and pipeline updates, centered on ARD-101 for Prader-Willi syndrome (PWS). The company is assessing unblinded Phase 3 HERO and OLE data in the third quarter of 2026 to evaluate overall efficacy and safety and inform next steps, while remaining in active discussions with the FDA to resolve the full clinical hold on the ARD-101 IND.The HERO and OLE trials were terminated in June 2026 and are not expected to resume as previously designed. As of June 30, 2026, Aardvark held $73.9 million in cash, cash equivalents and short-term investments, which it expects to fund operations into late 2027. Second quarter 2026 R&D expenses were $10.5 million (down from $13.1 million a year earlier), G&A expenses were $4.6 million (up from $2.7 million), and net loss was $14.4 million, roughly unchanged from the prior-year quarter.

Aardvark Therapeutics has faced another setback as the FDA places a hold on its main drug candidate, leading to a significant drop in stock value. Investors are urged to remain vigilant.

Aardvark Therapeutics experiences another major stock drop following FDA's clinical hold on its lead drug. Investigation into potential investor miscommunication continues.

Aardvark Therapeutics' stock plummets after they pause a crucial drug trial. An investigation into their disclosures and communications is underway.

...'on the fly' AI in White House post 'AI Czar' David Sacks